IDO/TDO inhibition is a topic we’ve been following the progress on for several years now with various updates along the way. It’s also one of our most requested Previews for this year’s ASCO meeting taking place next month.
In Chicago next month, initial data from several trials is due to be presented.
- What can we expect?
- How are the main players in this landscape doing?
- Will this combination be the next big thing in the oncology IO space?
In our latest #ASCO17 Preview, we take a hard look at IDO/TDO inhibitors.